ALX Oncology Narrows Q2 Loss by 34% Amid R&D Spend Cuts

TL;DR

**ALXO is burning less cash, but the massive R&D cut could signal a slowdown in pipeline progress, making it a risky bet for growth-focused investors.**

AI Summary

ALX Oncology Holdings Inc. reported a net loss of $25.949 million for the three months ended June 30, 2025, a significant improvement from the $39.399 million net loss in the same period of 2024, representing a 34.1% reduction. For the six months ended June 30, 2025, the net loss was $56.703 million, down from $74.980 million in 2024, a 24.3% decrease. Research and development expenses decreased substantially to $18.022 million for the three months ended June 30, 2025, from $34.653 million in 2024, a 48.0% reduction, and to $41.910 million for the six months ended June 30, 2025, from $66.370 million in 2024, a 36.8% decrease. General and administrative expenses also saw a decline, from $6.872 million to $5.451 million for the three-month period. The company's total assets decreased from $147.775 million as of December 31, 2024, to $95.320 million as of June 30, 2025, primarily due to a reduction in short-term investments from $110.190 million to $60.012 million. Cash and cash equivalents increased slightly from $17.567 million to $19.302 million. An impairment charge of $3.175 million was recorded for the current quarter, which was not present in the prior year. The company believes its existing capital resources will be sufficient to fund projected operating requirements for at least the next twelve months.

Why It Matters

ALX Oncology's reduced net loss and R&D expenses signal a potential shift in operational strategy, which could impact investor confidence and future drug development timelines. While a smaller loss is positive, the significant cut in R&D spending, nearly 50% year-over-year for the quarter, raises questions about the pace of their clinical pipeline advancement and competitive positioning against larger biotech firms. Employees might face uncertainty regarding program prioritization, and customers (future patients) could see delays in new therapies. The broader market will watch if this trend indicates a more sustainable financial path or a slowdown in innovation within the oncology space.

Risk Assessment

Risk Level: high — The company reported a substantial accumulated deficit of $677.825 million as of June 30, 2025, and continues to incur significant net losses, including $25.949 million for the quarter. While R&D expenses decreased, the company explicitly states it expects to incur additional losses and will likely require additional capital, with no assurance of successful funding, indicating high financial risk.

Analyst Insight

Investors should closely monitor ALX Oncology's upcoming clinical trial milestones and future financing activities. Given the high burn rate and reliance on future capital, a 'wait and see' approach is prudent until there's clearer visibility on pipeline progress or a successful capital raise.

Financial Highlights

debt To Equity

0.48

revenue

N/A

operating Margin

N/A

total Assets

$95.320M

total Debt

$10.040M

net Income

-$25.949M

eps

-$0.49

gross Margin

N/A

cash Position

$19.302M

revenue Growth

N/A

Key Numbers

• $25.949M — Net Loss (Q2 2025) (34.1% decrease from $39.399M in Q2 2024)
• $18.022M — R&D Expenses (Q2 2025) (48.0% decrease from $34.653M in Q2 2024)
• $56.703M — Net Loss (Six Months 2025) (24.3% decrease from $74.980M in Six Months 2024)
• $41.910M — R&D Expenses (Six Months 2025) (36.8% decrease from $66.370M in Six Months 2024)
• $677.825M — Accumulated Deficit (Increased from $621.122M as of Dec 31, 2024)
• $19.302M — Cash and Cash Equivalents (Slight increase from $17.567M as of Dec 31, 2024)
• $60.012M — Short-term Investments (Significant decrease from $110.190M as of Dec 31, 2024)
• $3.175M — Impairment Charge (New charge in Q2 2025, not present in Q2 2024)
• 53,551,134 — Common Stock Outstanding (As of August 5, 2025)

Key Players & Entities

• ALX ONCOLOGY HOLDINGS INC. (company) — Registrant in 10-Q filing
• $25.949 million (dollar_amount) — Net loss for Q2 2025
• $39.399 million (dollar_amount) — Net loss for Q2 2024
• $18.022 million (dollar_amount) — Research and development expenses for Q2 2025
• $34.653 million (dollar_amount) — Research and development expenses for Q2 2024
• $677.825 million (dollar_amount) — Accumulated deficit as of June 30, 2025
• $19.302 million (dollar_amount) — Cash and cash equivalents as of June 30, 2025
• $110.190 million (dollar_amount) — Short-term investments as of December 31, 2024
• $60.012 million (dollar_amount) — Short-term investments as of June 30, 2025
• Nasdaq Global Select Market (regulator) — Exchange where ALXO common stock is registered

FAQ

Risk Factors

• Cash Burn and Future Funding Needs [high — financial]: The company reported a net loss of $25.949 million for Q2 2025 and $56.703 million for the first six months of 2025. While management believes current capital resources are sufficient for the next twelve months, the continued operating losses and a significant decrease in short-term investments from $110.190 million to $60.012 million highlight the ongoing need for substantial funding to support operations and development.
• Dependence on Research and Development Success [high — operational]: ALX Oncology's core business relies heavily on the success of its research and development efforts in oncology. The company significantly reduced R&D expenses by 48.0% to $18.022 million in Q2 2025 and by 36.8% to $41.910 million for the six-month period. While this reduction contributes to improved net loss, any setbacks or delays in drug development could severely impact future revenue and market position.
• Accumulated Deficit [high — financial]: The company's accumulated deficit increased to $677.825 million as of June 30, 2025, from $621.122 million as of December 31, 2024. This substantial and growing deficit indicates a history of unprofitability and raises concerns about the long-term financial viability without significant future revenue generation or financing.
• Asset Reduction and Investment Strategy [medium — operational]: Total assets decreased by approximately 35.5% from $147.775 million to $95.320 million between December 31, 2024, and June 30, 2025. This was primarily driven by a reduction in short-term investments ($110.190M to $60.012M), suggesting a potential shift in liquidity management or funding needs. The decrease in property and equipment also indicates a scaling back of physical assets.
• Impairment Charge [medium — operational]: A new impairment charge of $3.175 million was recorded in the three and six months ended June 30, 2025. While not present in the prior year, this charge indicates a potential write-down of assets, which could signal issues with the valuation or performance of certain company assets.
• Clinical Trial and Regulatory Approval Risks [high — regulatory]: As a biotechnology company focused on oncology, ALX Oncology is subject to extensive regulatory scrutiny from bodies like the FDA. Delays or failures in clinical trials, or inability to secure regulatory approvals for its drug candidates, pose significant risks to the company's ability to bring products to market and generate revenue.
• Competitive Landscape in Oncology [medium — market]: The oncology market is highly competitive, with numerous established pharmaceutical companies and emerging biotechs vying for market share. ALX Oncology faces the risk of being outmaneuvered by competitors with more advanced pipelines, greater resources, or faster development timelines.
• Interest Expense and Debt Obligations [low — financial]: While interest income ($1.106M in Q2 2025) partially offsets interest expense ($405K in Q2 2025), the company carries a term loan with current and non-current portions totaling $10.040 million as of June 30, 2025. Servicing this debt adds to the financial burden, especially in the context of ongoing operating losses.

Industry Context

ALX Oncology operates in the highly competitive and rapidly evolving oncology drug development sector. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory requirements. Success hinges on innovation, clinical trial outcomes, and the ability to navigate complex regulatory pathways. Key trends include the rise of targeted therapies, immunotherapies, and personalized medicine approaches.

Regulatory Implications

As a clinical-stage biopharmaceutical company, ALX Oncology is subject to rigorous oversight by regulatory bodies like the FDA. Any delays or adverse findings in clinical trials, or challenges in obtaining marketing approval for its drug candidates, could significantly impact its financial performance and future prospects. Compliance with evolving healthcare regulations and data privacy laws is also critical.

What Investors Should Do

1. Monitor R&D Pipeline Progress
2. Evaluate Cash Burn Rate and Future Funding
3. Analyze Asset Composition Changes
4. Assess Competitive Positioning

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the condensed consolidated financial statements, showing reduced net loss and R&D expenses compared to the prior year, but also a significant decrease in total assets and short-term investments.
• 2024-12-31: End of Fiscal Year 2024 — Balance sheet comparison point, showing higher total assets and short-term investments compared to June 30, 2025.

Glossary

Accumulated Deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total loss incurred by the company since its inception. (Indicates the company's historical unprofitability, which stood at $677.825 million as of June 30, 2025.)

Impairment Charge

A reduction in the carrying value of an asset on the balance sheet when its fair value is less than its book value. (A new $3.175 million charge in Q2 2025 suggests a potential decrease in the value of certain company assets.)

Short-term Investments

Investments that are expected to be converted into cash within one year. (A significant decrease from $110.190 million to $60.012 million impacts the company's overall asset base and liquidity.)

Research and Development (R&D) Expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (A substantial decrease of 48.0% in Q2 2025 reflects cost-saving measures but also potential shifts in development strategy.)

Weighted-average shares of common stock

The average number of outstanding shares over a period, used for calculating earnings per share (EPS). (Used to calculate the net loss per share, which was -$0.49 for Q2 2025.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, ALX Oncology Holdings Inc. has demonstrated a significant reduction in net losses, with Q2 2025 losses down 34.1% and six-month losses down 24.3%. This improvement is largely attributable to a substantial decrease in Research and Development expenses, which fell by 48.0% for the quarter and 36.8% for the six months. However, total assets have decreased by approximately 35.5% due to a significant reduction in short-term investments, while the accumulated deficit has continued to grow. A new impairment charge of $3.175 million was noted in the current period, absent in the prior year.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ALXO The Nasdaq Global Se

Filing Documents

• alxo-20250630.htm (10-Q) — 2931KB
• alxo-ex31_1.htm (EX-31.1) — 18KB
• alxo-ex31_2.htm (EX-31.2) — 18KB
• alxo-ex32_1.htm (EX-32.1) — 11KB
• alxo-ex32_2.htm (EX-32.2) — 11KB
• 0000950170-25-107303.txt ( ) — 10242KB
• alxo-20250630.xsd (EX-101.SCH) — 1097KB
• alxo-20250630_htm.xml (XML) — 1941KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Comprehensive Loss 7 Condensed Consolidated Statements of Stockholders' Equity 8 Condensed Consolidated Statements of Cash Flows 9 Notes to Condensed Consolidated Financial Statements 10 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 33 Item 4

Controls and Procedures

Controls and Procedures 34 PART II OTHER INFORMATION Item 1

Legal Proceedings

Legal Proceedings 35 Item 1A

Risk Factors

Risk Factors 35 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 83 Item 3 Defaults Upon Senior Securities 83 Item 4 Mine Safety Disclosures 83 Item 5 Other Information 83 Item 6 Exhibits 84

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) ALX ONCOLOGY HOLDINGS INC. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share amounts) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 19,302 $ 17,567 Short-term investments 60,012 110,190 Prepaid expenses and other current assets 5,943 6,595 Total current assets 85,257 134,352 Property and equipment, net 1,497 2,905 Long-term investments 4,232 3,524 Other assets 4,334 6,994 Total assets $ 95,320 $ 147,775 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 4,902 $ 4,497 Payable and accrued liabilities due to related party 40 149 Term loan, current 3,043 435 Accrued expenses and other current liabilities 10,863 13,419 Total current liabilities 18,848 18,500 Term loan, non-current 6,997 9,469 Other non-current liabilities 5,060 6,188 Total liabilities 30,905 34,157 Commitments and contingencies (Note 12) Stockholders' equity Common stock, $ 0.001 par value; 1,000,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 53,506,777 and 53,052,912 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 54 53 Additional paid-in capital 742,150 734,412 Accumulated other comprehensive income 36 275 Accumulated deficit ( 677,825 ) ( 621,122 ) Total stockholders' equity 64,415 113,618 Total liabilities and stockholders' equity $ 95,320 $ 147,775 See accompanying notes to these condensed consolidated financial statements (unaudited). 5 ALX ONCOLOGY HOLDINGS INC. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share amounts) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Operating expenses: Research and developme

View Full Filing

View this 10-Q filing on SEC EDGAR